Ticker

Analyst Price Targets — CALC

Page 1 • Showing up to 10
DateAnalystFirmTargetPrice @ PostSourceHeadline
May 20, 2024 6:51 amLeland GershallOppenheimer$14.00$5.45StreetInsider Oppenheimer Reiterates Outperform Rating on CalciMedica (CALC)
November 22, 2022 2:31 pmChristopher RaymondRaymond James$392.00$146.90TheFly Piper Sandler keeps Neutral on Graybug Vision following CalciMedica merger news
May 18, 2022 9:13 pmChristopher RaymondPiper Sandler$392.00$171.81TheFly Graybug Vision price target lowered to $2 from $4 at Piper Sandler

Latest News for CALC

CalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension Program

Proceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027 Anticipated cash runway into 2H 2027 with upfront proceeds LA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the…

PRNewsWire • Jun 24, 2026
CalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety Data

FDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patients No comments or questions were received Confirms CalciMedica's ability to continue clinical development of Auxora across indications LA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing…

PRNewsWire • Jun 24, 2026
CalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate Updates

FDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027 LA JOLLA, Calif., May 12, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC),…

PRNewsWire • May 12, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for CALC.

No House trades found for CALC.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top